pibrentasvir

antiviral, a component of Mavyret

Also Known As:

A-1325912.0; ABT-530; dimethyl N,N'-(((2R,5R)-1-(3,5-difluoro-4-(4-(4-fluorophenyl)piperidin-1-yl)phenyl)pyrrolidine-2,5-diyl)bis((6-fluoro-1h-benzimidazole-5,2-diyl)((2S)-pyrrolidine-2,1-diyl)((2S,3R)-3-methoxy-1-oxobutane-1,2-diyl)))biscarbamate

Networked: 45 relevant articles (5 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - pibrentasvir: 45
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzimidazoles: 245
      - pibrentasvir: 45

Experts

1.	Asatryan, Armen: 11 articles (01/2020 - 12/2015)
2.	Mensa, Federico J: 11 articles (10/2019 - 10/2016)
3.	Kort, Jens: 9 articles (01/2019 - 12/2015)
4.	Lin, Chih-Wei: 8 articles (01/2020 - 12/2015)
5.	Liu, Wei: 8 articles (01/2020 - 12/2015)
6.	Gane, Edward: 8 articles (10/2019 - 10/2016)
7.	Ng, Teresa I: 8 articles (01/2019 - 12/2015)
8.	Wang, Stanley: 6 articles (10/2019 - 10/2016)
9.	Poordad, Fred: 5 articles (10/2019 - 01/2016)
10.	Chayama, Kazuaki: 4 articles (04/2020 - 01/2018)

Related Diseases

1.	Infections 06/01/2019 - "We describe here a case of a chronic HCV infection in a patient with end-stage renal disease, successfully treated with gleсaprevir/pibrentasvir (GLE/PIB). " 01/01/2019 - "Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. " 01/01/2016 - "Results from this study show that ABT-530 holds promise as part of a direct-acting antiviral treatment regimen for HCV genotype 3 infection." 01/01/2023 - "Furthermore, atovaquone, but not pibrentasvir, is observed to modulate HCoV-OC43 dsRNA and infection in a manner consistent with nsp15 inhibition. " 01/01/2017 - "Of the 449 patients who received varying doses of glecaprevir plus pibrentasvir, 25%, 29%, 39%, and 8% had HCV genotype 1, 2, 3, and 4-6 infection, respectively. "
2.	Chronic Hepatitis C 01/01/2023 - "The aims of the present study were to evaluate the real-life efficacy and tolerability of glecaprevir (GLE)/pibrentasvir (PIB) in the treatment of patients with chronic hepatitis C (CHC). " 10/01/2019 - "This study aims to investigate the efficacy and safety of the fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) (GLE/PIB) for patients with GT2 chronic hepatitis C. " 01/01/2018 - "Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection." 08/01/2021 - "A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. " 01/01/2022 - "Glecaprevir (GLE)/pibrentasvir (PIB) is a pangenotypic direct-acting antiviral regimen approved for treating chronic hepatitis C virus. "
3.	Fibrosis (Cirrhosis) 10/30/2019 - "PK analysis demonstrated a 2.2-fold increase in glecaprevir exposure, but not pibrentasvir exposure, in patients with compensated cirrhosis. " 01/01/2017 - "Glecaprevir plus pibrentasvir was well tolerated and achieved high sustained virologic response rates in HCV genotypes 1-6-infected patients without cirrhosis following 8- or 12-week treatment durations. " 10/01/2016 - "High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis." 10/25/2023 - "Glecaprevir (GLE) and pibrentasvir (PIB) are pangenotypic DAAs that are delivered alone or as a fixed-dose oral formulation to treat chronic HCV infections with or without cirrhosis. " 01/01/2018 - "We evaluated the efficacy and safety of 8-week and 12-week courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. "
4.	Neoplasms (Cancer) 06/01/2021 - "The current study throws new light on pibrentasvir, venetoclax, and ledipasvir as curative options for multidrug resistant cancers by inhibiting ABCG2 transporter."
5.	Liver Diseases (Liver Disease) 10/12/2017 - "We conducted a multicenter, open-label, phase 3 trial to evaluate the efficacy and safety of treatment with the combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir for 12 weeks in adults who had HCV genotype 1, 2, 3, 4, 5, or 6 infection and also had compensated liver disease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both. "

Related Drugs and Biologics

1.	glecaprevir
2.	Antiviral Agents (Antivirals)
3.	Protease Inhibitors (Protease Inhibitor)
4.	Ribavirin (Virazole)
5.	Sofosbuvir
6.	velpatasvir
7.	Simeprevir
8.	voxilaprevir
9.	sofosbuvir drug combination ledipasvir
10.	ledipasvir

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Liver Transplantation
4.	Aftercare (After-Treatment)
5.	Duration of Therapy